Dr. Roberto Pietro Antonacci Joins Applied Biomedical as Chief Medical Officer and as member of the Scientific Advisory Board

Lake Grove, NY – October 28th, 2024 – Applied Biomedical, a leading innovator in medical biotechnology, is proud to announce the appointment of Roberto Pietro Antonacci, M.D., as Chief Medical Officer and member of the company’s Scientific Advisory Board. Dr. Antonacci brings a wealth of experience in medical leadership, oncologic and diagnostic imaging knowledge as well as clinical research, positioning him as a pivotal addition to the team as Applied Biomedical continues to advance its cutting-edge rapid diagnostics and medical solutions.

Dr. Antonacci holds a Medical Doctorate from Albany Medical College and has completed post-graduate training in Radiation Oncology at New York Presbyterian Hospital. His career is distinguished by significant contributions to medical research, including clinical prognostic indicators in breast cancer tumors and the use of MR imaging in staging prostate cancer.

With a career spanning over two decades, Dr. Antonacci has held prominent roles in the medical field, including serving as President of Suffolk Breast Imaging, PC, and North Shore Regional MRI, PC, where he has driven rapid growth and expanded access to critical cancer screening services across Long Island, NY. He is also currently the Chief Medical Officer of Green Express Med, LLC, where he oversees the development and implementation of novel medical cannabis therapeutics as well as initiation of federal & New York State grantsmanship to fund public health strategies for key populations through medical cannabis dispensaries in NYS.

At Applied Biomedical, Dr. Antonacci will spearhead the clinical strategies for the company’s medical innovations focusing on federal research funding and advancing the development of rapid diagnostics. His deep understanding of oncology, diagnostic imaging, cancer screening, and translational research will be instrumental in guiding the company’s strategic initiatives in healthcare with Point of Care rapid diagnostics for early detection and prevention of diseases.

“I am excited to join Applied Biomedical at this transformative time,” said Dr. Antonacci. “The company’s innovative approach to biotechnology aligns perfectly with my passion for improving patient care through advanced diagnostics, early detection and medical outcome research. I look forward to contributing to the company’s mission and helping to drive its clinical strategy forward.”

Applied Biomedical’ CEO expressed enthusiasm about the appointment, stating: “Dr. Antonacci’s expertise and leadership will be invaluable as we expand our product offerings and push forward in the development of breakthrough medical technologies. His background in oncology, cancer screening and diagnostic imaging adds tremendous value to our efforts in creating more accessible, efficient healthcare solutions.”